Cefuroxime Axetil

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

58 API Suppliers, 39 USDMF, 21 CEP/COS, 10 EU WC, 22 KDMF, 4 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

221 FDF Dossiers, 34 FDA Orange Book, 112 Europe, 5 Canada, 8 South Africa, 62 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML, FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

1 Evonik, 4 Rochem International Inc, 19 SPI Pharma, 2 Seqens, 7 DKSH, 1 Pharm-RX Chemical, 5 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 19 BASF, 2 Clariant, 12 Corel Pharma Chem, 3 DFE Pharma, 2 Finar, 9 Gangwal Chemicals, 9 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 17 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders, 56 Coating Systems & Additives, 37 Direct Compression, 32 Controlled & Modified Release, 29 Thickeners and Stabilizers, 28 Lubricants & Glidants, 22 Taste Masking, 21 Solubilizers, 20 Topical, 19 Disintegrants & Superdisintegrants, 19 Granulation, 19 Co-Processed Excipients, 18 Chewable & Orodispersible Aids, 18 Parenteral, 16 Film Formers & Plasticizers, 11 Emulsifying Agents, 8 API Stability Enhancers, 7 Rheology Modifiers, 5 Surfactant & Foaming Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 112 Finished Drug Prices

MARKET PLACE

25 APIs, 30 FDF Dossiers

PATENTS & EXCLUSIVITIES

9 Health Canada Patents

9 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 3 USP, 5 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 50605 / DOSAGE - TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
CEFUROXIME AXETIL(UNII: Z49QDT0J8Z) (CEFUROXIME - UNII:O1R9FJ93ED)	CEFUROXIME	250mg in 5 \| 125mg in 5 \| 250mg

Inactive Ingredients

Ingredient Name	GlaxoSmithKline LLC
ACESULFAME POTASSIUM(23OV73Q5G9)
ASPARTAME(Z0H242BBR1)
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
CROSCARMELLOSE SODIUM(M28OL1HH48)
HYPROMELLOSES(3NXW29V3WO)
METHYLPARABEN(A2I8C7HI9T)
POVIDONE K30(U725QWY32X)
PROPYLENE GLYCOL(6DC9Q167V3)
PROPYLPARABEN(Z8IX2SC1OH)
SILICON DIOXIDE(ETJ7Z6XBU4)
SODIUM BENZOATE(OJ245FE5EU)
SODIUM LAURYL SULFATE(368GB5141J)
STEARIC ACID(4ELV7Z65AP)
SUCROSE(C151H8M554)
TITANIUM DIOXIDE(15FIX9V2JP)
XANTHAN GUM(TTV12P4NEE)

Drug Product Composition: Cefuroxime Axetil